Assertio Holdings

ASRTPhase 2

Assertio Holdings is a specialty pharmaceutical company that acquires, develops, and commercializes products primarily in pain management and neurology. The company's strategy centers on leveraging its commercial infrastructure to maximize the value of its marketed products, which include INDOCIN and other established therapies. While navigating challenges such as generic competition and patent expirations, Assertio aims to grow through strategic business development and lifecycle management of its portfolio.

Market Cap

$86.2M

Employees

50-100

Focus

Biotech

ASRT · Stock Price

USD 13.3725.63 (-65.72%)

Historical price data

AI Company Overview

Technology Platform

Commercial and development platform focused on acquiring and maximizing the value of established or late-stage pharmaceutical products through regulatory strategy and targeted commercialization.

Pipeline Snapshot

1 drug in pipeline

Drug	Indication	Stage
Ketorolac + Prochlorperazine + Diphenhydramine	Headache, Migraine	Phase 2

Opportunities

Opportunities include leveraging capital from recent divestitures to acquire new commercial or late-stage products, expanding the label or formulations of INDOCIN, and executing a focused growth strategy in niche specialty pharmaceutical markets.

Risk Factors

Key risks include heavy reliance on a single product (INDOCIN), exposure to generic competition, challenges in executing business development to acquire new assets, and integration risks associated with any future acquisitions.

Competitive Landscape

Assertio competes in crowded generic markets for NSAIDs and faces competition in the neonatal PDA treatment space. Its differentiation is based on specific formulations, brand recognition in niches, and a lean, targeted commercial approach rather than novel drug discovery.